Clinical trials: Schizophrenia Spectrum Disorder
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant
This is an Open-Label Study in Stable Schizophrenia Patients to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Risperidone to Risperidone Implant (DLP-114).
- Trial name
- DLP-114 (NCT04418466)
- Testing
- Risperidone
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Delpor, Inc.
Schizophrenia
Patient-Centered Medication Adherence Intervention for Schizophrenia
Efficacious antipsychotic medication treatments for schizophrenia are available; however , antipsychotic regimens frequently do not achieve their potential because of poor medication adherence.
- Trial name
- AMAIS (NCT00144027)
- Testing
- Antipsychotic medication adherence intervention
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia
Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia
To characterize the pharmacokinetics (PK) of the injectable intramuscular (IM) long-acting formulation (in situ microparticle, ISM) of risperidone over four IM injections in the gluteal and deltoid muscle at 28-day intervals and…
- Trial name
- PRISMA-2 (NCT02086786)
- Testing
- Risperidone ISM
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Schizophrenia
The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia
The primary objectives of this application are to determine if the selective ERβ agonist LY500307, when added to antipsychotic medications, improves negative and/or cognitive symptoms in patients with schizophrenia.
- Trial name
- Beta (NCT01874756)
- Testing
- LY500307 150mg, LY500307 75mg, LY500307 25mg
- Where
- 4 sites in United States
- Volunteers
- 95 people
- Sponsor
- Indiana University
Psychotic Disorders, Obesity
Web-Based Delivery of MOVE! to Veterans With Serious Mental Illness (SMI)
Obesity and physical inactivity have reached epidemic proportions, resulting in increased rates of a variety of chronic diseases, increased risk of death, and substantial health care costs.
- Conditions
- Psychotic Disorders, Obesity, Health Behaviors
- Trial name
- Web-MOVE! (NCT00983476)
- Testing
- in-person MOVE! SMI, web-based MOVE! SMI
- Where
- United States
- Volunteers
- 276 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Auditory Hallucination
Boost rTMS for Auditory Verbal Hallucinations
This is a randomized, placebo controlled, double-blind clinical trial. The investigators aim to examine the safety and efficacy of repeated transcranial magnetic stimulation (rTMS) for the treatment of auditory verbal…
- Trial name
- NCT03544333
- Testing
- transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Northwell Health
Schizophrenia
Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031
Open label extension study of Ziprasidone, evaluation of safety of long term use of ziprasidone
- Trial name
- NCT00174447
- Testing
- Ziprasidone
- Where
- 14 sites in France
- Volunteers
- 43 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years
The purpose of this study is to evaluate the effectiveness and safety of paliperidone extended release (ER) in symptomatic participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment…
- Trial name
- NCT01362439
- Testing
- Paliperidone ER
- Volunteers
- 133 people
- Sponsor
- Janssen-Cilag S.p.A.
Parkinson's Disease
A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease
The major purpose of the Stage 1 is to study the safety and tolerability of the proposed dosage regimen of the study drug. The form of cannabidiol (CBD) used in this study is GWP42003, supplied by GW Pharmaceuticals.
- Trial name
- NCT02818777
- Testing
- cannabidiol
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Schizophrenia
Oral Aripiprazole Open-Label Rollover Study
The purpose of this study is to test the long-term safety and tolerability of oral aripiprazole in adolescent patients with schizophrenia.
- Trial name
- NCT01001702
- Testing
- Aripiprazole
- Where
- 15 sites in Argentina, Croatia and 4 more
- Volunteers
- 85 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia
This is a pilot study of pregnenolone as an augmentation treatment for schizophrenia. The goal of this placebo-controlled study is to provide preliminary efficacy data for potential pregnenolone effects on cognitive symptoms and…
- Trial name
- NCT00560937
- Testing
- Pregnenolone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Durham VA Medical Center
Schizophrenia, Major Depressive Disorder
Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System
This study will assess the helpfulness of the integrated call center in optimizing use of the Digital Medicine System in adult subjects with Schizophrenia, Major Depressive Disorder, or Bipolar Disorder taking oral aripiprazole.
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT02722967
- Testing
- Aripiprazole + IEM (Ingestible Event Marker)
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Effect of Single Dose Intranasal Insulin On Cognitive Function
The purpose of the study is to find out how a small dose of insulin might affect memory, the ability to concentrate, and improve your daily functioning in patients with schizophrenia and schizoaffective disorders.
- Trial name
- NCT00646581
- Testing
- Insulin (Humulin)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Schizophrenia
Aripiprazole, Abilify Maintena Collaborative Clinical Protocol
An Open-label, Multi-center, Longitudinal, Within-subject Comparison Study to Evaluate the Effects of Aripiprazole Once Monthly in Subjects with Schizophrenia on 30-, 90-, and 180- day Re-hospitalization Rates Following Hospital…
- Trial name
- NCT02717130
- Testing
- Aripiprazole
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Florida Atlantic University
Schizophrenia, Schizoaffective Disorder
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.
- Trial name
- SWITCHCore (NCT01143077)
- Testing
- Lurasidone HCl
- Where
- 27 sites in United States
- Volunteers
- 244 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia Spectrum and Other Psychotic Disorders, Cognitive Impairment
Repetitive TMS & Cognitive Training in Adults With Schizophrenia
The proposed project aims to establish the feasibility and tolerability of delivering repetitive transcranial magnetic stimulant (rTMS) combined with computerized cognitive training in patients with Schizophrenia or…
- Trial name
- CrTMS (NCT03741751)
- Testing
- rTMS, Computerized cognitive training
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Washington University School of Medicine
Schizophrenia
Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
This study will determine whether adding the drug risperidone (Risperdal®) is more effective than placebo in treating schizophrenic patients who are taking the drug clozapine.
- Trial name
- NCT00056498
- Testing
- Risperdal
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia
The purpose of this trial is to evaluate the dose distribution, effectiveness and safety in patients with schizophrenia who are switched from an oral atypical antipsychotic to Paliperidone ER.
- Trial name
- NCT00473434
- Testing
- Paliperidone
- Volunteers
- 64 people
- Sponsor
- Janssen-Cilag Pty Ltd
Schizophrenia
Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia
This is a study of a new medication for the treatment of cognitive impairments (thinking difficulties) and negative symptoms in people with schizophrenia. The new medication is rasagiline.
- Trial name
- NCT00492336
- Testing
- rasagiline (Pharmacodynamics)
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism
This is a Phase 4, randomized, open-label, parallel group study designed to assess the clinical and biological effects of 12 months of treatment with long acting intramuscular (IM) aripiprazole (Abilify®) as measured by clinical…
- Trial name
- NCT02237417
- Testing
- Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Utah